Chemotherapy-Induced Neutropenia: Impact on Cancer Care

EP: 1.Facts About Chemotherapy-Induced Neutropenia

Now Viewing

EP: 2.Chemotherapy-Induced Neutropenia: Impact on Cancer Care

EP: 3.Monitoring for Chemotherapy-Induced Neutropenia

EP: 4.Considerations for Chemotherapy-Induced Neutropenia Prophylaxis

EP: 5.Chemotherapy-Induced Neutropenia Prophylaxis: Standard of Care

EP: 6.CIN Prophylaxis: Treating With G-CSFs

EP: 7.Plinabulin With G-CSF Treatment for CIN Prophylaxis

EP: 8.CIN Prophylaxis: NCCN’s Reactions to COVID-19

EP: 9.Chemotherapy-Induced Neutropenia: Financial Burden

EP: 10.Health Plans React to Chemotherapy-Induced Neutropenia

EP: 11.Reducing the Risk of Chemotherapy-Induced Neutropenia

EP: 12.At-Home Administration of CIN Prophylaxis

EP: 13.Coverage for Chemotherapy-Induced Neutropenia

Lee Schwartsberg, MD, FACP: CIN [chemotherapy-induced neutropenia] affects cancer care in several ways. First of all, if a patient develops chemotherapy-induced neutropenia, there may be a delay in recovery of the [neutrophil] counts, and therefore the patient may not start their next scheduled dose on time. If this happens multiple times, the patient will not receive the full dose of therapy on schedule, and we’ve learned over the years that that’s an important component of outcome.

For patients who receive, particularly in a curative setting, chemotherapy that’s less than 85% of the calculated dose when you start, based on the clinical trials that prove the efficacy of that regimen, the outcome for patients who receive less than full dose on schedule can be compromised. What we mean by that is that patients may have increased mortality in a curative setting if they get less than 85% of the planned dose on schedule. If there is a dose delay, if the physician modifies the dose, which frequently happens when a patient develops CIN and then febrile neutropenia, they may get a reduction in their dose in subsequent cycles of therapy.

The combination of dose modifications and dose delays can reduce the total dose of curative therapy given, which can lead to a poorer outcome.

In rare cases, patients may have to discontinue therapy completely if they had a severe complication of CIN. The severe complications of CIN include an unplanned visit to the clinic to get hydration or antibiotics, or even more commonly emergency department visits, admissions to the hospital for febrile neutropenia, which require IV [intravenous] treatment including IV antibiotics, and treatment of those patients who can become very sick.

For the patients in my experience who do have an episode of febrile neutropenia and prolonged hospitalization, they may often not continue their chemotherapy, and therefore, not get the benefit out of that type of treatment.